Medicare Enrolled

Dr. Scott Godfrey, DO

Hematology & Oncology · San Diego, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
4647 ZION AVE, San Diego, CA 92120
6195285000
In practice since 2006 (19 years)
NPI: 1659464089 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Godfrey from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Godfrey? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Godfrey

Dr. Scott Godfrey is a hematology & oncology specialist in San Diego, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Godfrey performed 1,679 Medicare services across 514 unique beneficiaries.

Between the years covered by Open Payments, Dr. Godfrey received a total of $6,682 from 34 pharmaceutical and/or device companies across 107 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Godfrey is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 42% volume in CA $6,682 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,679
Medicare services
Top 42% in CA for hematology & oncology
514
Unique beneficiaries
$44
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~88 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Dexamethasone injection (steroid)
An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram.
510 $0 $0
Anti-nausea injection (Aloxi/palonosetron) 320 $1 $9
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
184 $106 $353
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
128 $72 $249
Intravenous injection of additional new drug or substance
Administration of an additional new medication or substance directly into a vein.
104 $14 $65
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
75 $120 $487
New patient office visit, complex (60-74 min) 68 $179 $597
Leuprolide acetate (for depot suspension), 7.5 mg 63 $133 $709
Intravenous infusion of new drug or substance, 1 hour or less
This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less.
37 $59 $241
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
35 $12 $69
Subcutaneous or intramuscular chemotherapy injection
This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle.
35 $30 $115
Additional sequential IV infusion, 1 hour or less
This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less.
26 $26 $106
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
26 $121 $453
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
26 $65 $189
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
23 $74 $349
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
19 $137 $491
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
8.2% high complexity
59.8% medium
32.0% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$6,682
Total received (2018-2024)
Avg $955/year across 7 years
Top 38% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
34
Companies
107
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,361 (80.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,198 (17.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$123 (1.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$3,031
2023
$1,739
2022
$1,045
2021
$180
2020
$122
2019
$125
2018
$441

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$1,198
Alexion Pharmaceuticals, Inc.
$338
E.R. Squibb & Sons, L.L.C.
$221
Janssen Biotech, Inc.
$173
PFIZER INC.
$171
ABBVIE INC.
$162
Astellas Pharma US Inc
$152
Melinta Therapeutics, LLC
$141
BeiGene USA, Inc.
$125
EMD Serono, Inc.
$105
Novartis Pharmaceuticals Corporation
$99
Incyte Corporation
$90
Genmab U.S., Inc.
$20
Abbott Laboratories
$19
Agios Pharmaceuticals, Inc.
$18
Top 3 companies account for 58.0% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$1,353
ABBVIE INC.
$504
Alexion Pharmaceuticals, Inc.
$463
Janssen Biotech, Inc.
$427
Astellas Pharma US Inc
$408
E.R. Squibb & Sons, L.L.C.
$353
Incyte Corporation
$328
Daiichi Sankyo Inc.
$309
Karyopharm Therapeutics Inc.
$247
Seagen Inc.
$196
PFIZER INC.
$187
GENZYME CORPORATION
$167
Melinta Therapeutics, LLC
$141
Monteris Medical Corporation
$130
BeiGene USA, Inc.
$125
Bayer HealthCare Pharmaceuticals Inc.
$125
Puma Biotechnology, Inc.
$125
Novartis Pharmaceuticals Corporation
$122
GlaxoSmithKline, LLC.
$120
Rigel Pharmaceuticals, Inc.
$105
JAZZ PHARMACEUTICALS INC.
$105
EMD Serono, Inc.
$105
EISAI INC.
$102
Gilead Sciences, Inc.
$96
Janssen Pharmaceuticals, Inc
$72
Lilly USA, LLC
$64
Genentech USA, Inc.
$40
Takeda Pharmaceuticals U.S.A., Inc.
$33
Adaptive Biotechnologies Corporation
$28
AVEO Pharmaceuticals, Inc.
$24
TerSera Therapeutics LLC
$22
Genmab U.S., Inc.
$20
Abbott Laboratories
$19
Agios Pharmaceuticals, Inc.
$18
Top 3 companies account for 34.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · BOSULIF · BRUKINSA · CALQUENCE · CARDIOMEMS · CARVYKTI · DARZALEX · ELREXFIO · ENHERTU · EPKINLY · Enhertu · Epkinly · FOTIVDA · Herceptin · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · JAKAFI · JEMPERLI · KISQALI · Kimyrsa · LYNPARZA · Lenvima · MEKINIST · Nerlynx · Neuroblate · OPDIVO · PROMACTA · PYRUKYND · REBLOZYL · Rezzayo · SARCLISA · TECENTRIQ · TECVAYLI · TIVDAK · Tavalisse · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VYXEOS · Vitrakvi · Vyloy · XARELTO · XPOVIO · Xospata · Xtandi · Zoladex · Zydelig · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (80%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a hematology & oncology specialist in San Diego?
Compare hematology & oncology specialists in the San Diego area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
131
Per 100K population
4.0
County median income
$102,285
Nearest hospital
KAISER FOUNDATION HOSPITAL - SAN DIEGO
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Godfrey is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Godfrey experienced with dexamethasone injection (steroid)?
Based on Medicare claims data, Dr. Godfrey performed 510 dexamethasone injection (steroid) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Godfrey receive payments from pharmaceutical companies?
Yes. Dr. Godfrey received a total of $6,682 from 34 companies across 107 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Godfrey's costs compare to other hematology & oncology specialists in San Diego?
Dr. Godfrey's average Medicare payment per service is $44. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Godfrey) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →